Novel Anticancer Strategies (Volume II)
Novel Anticancer Strategies (Volume II) reviews important findings and updates within the cancer therapy field of great interest to those in academic research studying the development and validation of novel anticancer approaches. The Editor invited preeminent specialists to contribute to original a...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_98933 | ||
| 005 | 20230405 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20230405s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-7032-7 | ||
| 020 | |a 9783036570334 | ||
| 020 | |a 9783036570327 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-7032-7 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 100 | 1 | |a Bousbaa, Hassan |4 edt | |
| 700 | 1 | |a Bousbaa, Hassan |4 oth | |
| 245 | 1 | 0 | |a Novel Anticancer Strategies (Volume II) |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 electronic resource (700 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Novel Anticancer Strategies (Volume II) reviews important findings and updates within the cancer therapy field of great interest to those in academic research studying the development and validation of novel anticancer approaches. The Editor invited preeminent specialists to contribute to original and review articles devoted to key areas of major progress and expectations. Key Features:Nanoparticle-based drug delivery in cancer therapy;Nanoerythrosomes;Cancer immunotherapy;Therapeutic vaccines;Oncogenic and tumor suppressive components of the cell cycle;Antimitotics in cancer clinical trials;Multifunctional enzymes as anti-cancer drug targets;Targeting undruggable proteins and non-coding RNAs;Cell-penetrating peptides;Repurposed cancer drugs in clinical trials;Circulating tumour cells. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 650 | 7 | |a Oncology |2 bicssc | |
| 653 | |a Breast cancer treatment | ||
| 653 | |a Photodynamic therapy | ||
| 653 | |a Inorganic nanoparticles | ||
| 653 | |a Active targeting | ||
| 653 | |a cathepsins | ||
| 653 | |a BAX | ||
| 653 | |a MOMP | ||
| 653 | |a ubiquitination | ||
| 653 | |a apoptosis | ||
| 653 | |a chemotherapy | ||
| 653 | |a cancer | ||
| 653 | |a nanoerythrosome | ||
| 653 | |a nanoerythrocyte | ||
| 653 | |a nanovesicles | ||
| 653 | |a biomimetic | ||
| 653 | |a cancer therapy | ||
| 653 | |a diagnostics | ||
| 653 | |a imaging agents | ||
| 653 | |a cell cycle | ||
| 653 | |a cyclin-dependent kinase | ||
| 653 | |a p16 | ||
| 653 | |a p21 | ||
| 653 | |a p27 | ||
| 653 | |a breast cancer | ||
| 653 | |a prognosis | ||
| 653 | |a drug delivery | ||
| 653 | |a HL60 | ||
| 653 | |a leukemia | ||
| 653 | |a prodrug | ||
| 653 | |a resistance | ||
| 653 | |a retinoic acid | ||
| 653 | |a vitamin K | ||
| 653 | |a drug repurposing | ||
| 653 | |a COVID-19 | ||
| 653 | |a pandemic | ||
| 653 | |a vaccination | ||
| 653 | |a multi-drug resistance | ||
| 653 | |a enhanced permeation and retention effect | ||
| 653 | |a nanotherapeutics | ||
| 653 | |a cancer theranostic | ||
| 653 | |a clinical translation | ||
| 653 | |a cell-penetrating peptides | ||
| 653 | |a protein transduction domains | ||
| 653 | |a tumor imaging | ||
| 653 | |a targeted therapies | ||
| 653 | |a dog | ||
| 653 | |a comparative oncology | ||
| 653 | |a molecular targets | ||
| 653 | |a spheroids | ||
| 653 | |a tumoroids | ||
| 653 | |a hydrogel | ||
| 653 | |a collagen | ||
| 653 | |a agarose | ||
| 653 | |a mammary spheroids | ||
| 653 | |a tissue engineering | ||
| 653 | |a cisplatin | ||
| 653 | |a melanoma | ||
| 653 | |a melanin nanoparticles | ||
| 653 | |a cytotoxicity | ||
| 653 | |a laser medical applications | ||
| 653 | |a hyperthermia | ||
| 653 | |a antimitotics | ||
| 653 | |a mitotic slippage | ||
| 653 | |a spindle assembly checkpoint | ||
| 653 | |a clinical trials | ||
| 653 | |a TRAIL | ||
| 653 | |a cancer stem cells | ||
| 653 | |a TRAIL resistance | ||
| 653 | |a angiogenesis | ||
| 653 | |a on-demand drug delivery systems | ||
| 653 | |a electrospun nanofibers | ||
| 653 | |a poly (N-isopropylacrylamide) | ||
| 653 | |a gold nanorods | ||
| 653 | |a paclitaxel | ||
| 653 | |a β-Cyclodextrin | ||
| 653 | |a SPIONs | ||
| 653 | |a metallodrugs | ||
| 653 | |a RAPTA derivatives | ||
| 653 | |a phosphino-amine ligands | ||
| 653 | |a CTCs | ||
| 653 | |a NSCLCs | ||
| 653 | |a metastasis suppression | ||
| 653 | |a curcumin | ||
| 653 | |a flavonoids | ||
| 653 | |a TNBC | ||
| 653 | |a immunotherapy | ||
| 653 | |a immune checkpoint | ||
| 653 | |a nanocarrier | ||
| 653 | |a combinational immunotherapy | ||
| 653 | |a lung cancer | ||
| 653 | |a miRNA | ||
| 653 | |a oncomiRs | ||
| 653 | |a photodynamic therapy PDT | ||
| 653 | |a porphyrin | ||
| 653 | |a iron oxide nanoparticles | ||
| 653 | |a mesoporous silica nanoparticles | ||
| 653 | |a antibody functionalization | ||
| 653 | |a targeted drug delivery systems | ||
| 653 | |a molecular-targeted therapies | ||
| 653 | |a multifunctional enzymes | ||
| 653 | |a HCC | ||
| 653 | |a CHRNA5 | ||
| 653 | |a metastasis | ||
| 653 | |a stemness property | ||
| 653 | |a sorafenib sensitivity | ||
| 653 | |a neoantigens | ||
| 653 | |a vaccine | ||
| 653 | |a Patched | ||
| 653 | |a chemotherapy resistance | ||
| 653 | |a metastases | ||
| 653 | |a persistent cells | ||
| 653 | |a adrenocortical carcinoma | ||
| 653 | |a BUB3 | ||
| 653 | |a mitosis | ||
| 653 | |a senescence | ||
| 653 | |a anticancer target | ||
| 653 | |a boron neutron capture therapy | ||
| 653 | |a 4-borono-l-phenylalanine | ||
| 653 | |a drug discovery | ||
| 653 | |a solubility | ||
| 653 | |a mebendazole | ||
| 653 | |a polymer | ||
| 653 | |a HPMA | ||
| 653 | |a controlled drug release | ||
| 653 | |a PLK1 | ||
| 653 | |a BI2536 | ||
| 653 | |a Navitoclax | ||
| 653 | |a slippage | ||
| 653 | |a PD-1 | ||
| 653 | |a gemcitabine | ||
| 653 | |a new anti-cancer drugs | ||
| 653 | |a precision medicine | ||
| 653 | |a undruggable targets | ||
| 653 | |a non-coding RNAs | ||
| 653 | |a oligonucleotide therapeutics | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/6986 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/98933 |7 0 |z DOAB: description of the publication |